Trial Profile
A phase I study of HT-3951 for the treatment of neurodegenerative disorders
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2015
Price :
$35
*
At a glance
- Drugs HT 3951 (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions
- 13 Apr 2015 New trial record